Santhera Pharmaceuticals Articles
IDSMB backs continuation of Santhera's Ph III Catena trial in DMD, but now needs partner
16 April 2013
Good EMA news for Pfizer's Bosulif but not for Santhera's Raxone
21 January 2013
Ipsen returns rights to Parkinson’s drug to Santhera
26 January 2012
Santhera licenses rights to PD drug candidate fipamezole to France’s Ipsen for more than 140 million euros
3 September 2010
Showing 1-5 of 5 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
